financetom
Business
financetom
/
Business
/
Northland Power Appoints John Brace as Interim President and CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Northland Power Appoints John Brace as Interim President and CEO
Oct 2, 2024 10:07 PM

08:28 AM EDT, 10/01/2024 (MT Newswires) -- Northland Power (NPI.TO) said on Tuesday that it appointed John Brace as interim president and CEO after the departure of Mike Crawley.

Brace has been serving as Northland's executive chair since March 25.

The company said Brace continues to serve as chair of the board while Ian Pearce continues as lead independent director.

Brace's "leadership and expertise have been instrumental as Northland continues to focus on its key priorities, including successfully advancing the Company's three large construction programs - Hai Long, Baltic Power and Oneida - as well as prudently advancing Northland's 9GW development pipeline," Northland said in a press release.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nigeria blocks Shell's asset sale in the Niger Delta
Nigeria blocks Shell's asset sale in the Niger Delta
Oct 21, 2024
ABUJA, Oct 21 (Reuters) - Nigeria has blocked the sale of Shell's entire onshore and shallow-water oil and gas assets in the Niger Delta, the country's upstream regulator said on Monday, roughly 10 months after the deal was announced. In a speech at an event in the capital Abuja, Nigerian Upstream Petroleum Regulatory Commission (NUPRC) CEO Gbenga Komolafe said the...
Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell
Regenxbio Reports 97% Reduction in Injection Need for Wet AMD; Shares Rise Pre-Bell
Oct 21, 2024
09:08 AM EDT, 10/21/2024 (MT Newswires) -- Regenxbio ( RGNX ) reported Monday a 97% reduction in anti-VEGF injections at nine months in a Phase II study of ABBV-RGX-314 for wet age-related macular degeneration, or AMD. In the subretinal treatment of the second eye, 78% of patients remained injection-free, the company said. Visual acuity and retinal thickness were maintained, with...
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Oct 21, 2024
Sanofi SA ( SNY ) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi’s consumer health unit.   The new step in Opella’s journey paves the way for creating a standalone player in consumer healthcare while supporting Sanofi’s strategy and increased focus on innovative...
Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing
Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing
Oct 21, 2024
08:45 AM EDT, 10/21/2024 (MT Newswires) -- Elisabet de los Pinos, Director, President and Chief Executive Officer, on October 18, 2024, sold 24,992 shares in Aura Biosciences ( AURA ) for $300,839. Following the Form 4 filing with the SEC, Elisabet de los Pinos has control over a total of 461,259 shares of the company, with 329,847 shares held directly...
Copyright 2023-2025 - www.financetom.com All Rights Reserved